Consuelo Giménez Pardo

Amid an unprecedented international security and coordination operation, the MV Hondius has arrived at the port of Granadilla, in Tenerife, where epidemiologists and members of the Foreign Health Service will examine the passengers and crew, who have not shown any symptoms of hantavirus so far. Once assessed, they will leave the ship, which is moored in a dock, in small boats to the port, grouped by nationality – they come from 23 different countries. From there, they will board military vehicles to reach Tenerife South Airport, from where they will be repatriated on various flights. The 14 Spaniards and a member of the WHO from Africa are bound for Gómez Ulla Hospital (Madrid) to undergo quarantine. Once the process is complete, the cruise ship will refuel and sail to the Netherlands with part of the crew on board and the body of one of the three fatalities.

The U.S. Presidential Malaria Initiative is a project that has been in place since 2005 to reduce malaria cases and deaths in Africa. The Donald Trump administration has halted some of its services and questioned its continuity. Now, a team has analyzed the possible consequences in 27 of the most affected countries on the continent. According to their estimates, some 104,000 deaths and around 13.6 million cases would be avoided if full funding were maintained. The results are published in The Lancet.  

A study has identified and tested 22 compounds that inhibit the development of Plasmodium falciparum—one of the parasites that cause malaria—in the mosquitoes that transmit it. The most effective molecule killed 100% of the parasites present within six minutes, even in insecticide-resistant mosquitoes, according to the study published in Nature. These compounds could be used to treat bed nets.

The RH5.1/Matrix-M vaccine is effective and safe against malaria, according to a phase 2b clinical trial in infants in Burkina Faso published in The Lancet Infectious Diseases. Two other vaccines are already approved against malaria, a disease caused by the Plasmodium falciparum parasite, but this one acts at a different stage of the disease: when the malaria parasite is present in the blood. The other two vaccines attack the parasite when reaches the liver.

In a clinical trial of nearly 5,000 children aged 5-36 months, a new malaria vaccine - called R21/MatrixM - reduced symptomatic cases by 68-75% over the following year. According to the authors, the vaccine will be inexpensive and could contribute to a substantial reduction in malaria suffering and deaths in sub-Saharan Africa. The results of the phase 3 trial are published in The Lancet.

The Centre for the Coordination of Alerts and Health Emergencies (CCAES) reported yesterday that last February Germany reported two cases of dengue (one confirmed and one probable), along with four cases compatible with epidemiological links, in residents of Germany who had travelled to Ibiza during the incubation period. One of the potential vectors of dengue is the Aedes albopictus mosquito, which was first detected in Ibiza in 2014. According to the CCAES, the risk of new autochthonous cases appearing in Ibiza, "at this time of low vector activity, is considered low".

An experimental malaria vaccine has shown protection for at least six months, according to a clinical trial in 112 adults in Burkina Faso. The results are published today in the journal Science Translational Medicine.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation for the tetravalent dengue vaccine (live, attenuated) Takeda. The vaccine is intended to prevent disease caused by dengue virus serotypes 1, 2, 3 and 4 in people aged four years and older. Although an approved vaccine already exists, according to the EMA, this quadrivalent vaccine shows increased protection in children and people over 45 years of age.